Guardant Health and Bayshore HealthCare Partner to Expand Access to Advanced Precision Oncology Testing in Canada
Guardant Health (Nasdaq: GH) has partnered with Bayshore HealthCare to expand access to precision oncology testing across Canada. The agreement will make Guardant's portfolio of cancer tests available through Bayshore's network of clinics, which serves over 350,000 Canadians annually (excluding Quebec).
The partnership includes three key tests: Guardant360® for therapy selection in advanced cancer, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring in early-stage cancer, and Shield™ blood test for colorectal cancer screening. This collaboration aims to provide physicians with advanced molecular profiling technology for developing personalized care plans and improving patient outcomes.
Guardant Health (Nasdaq: GH) ha stipulato una partnership con Bayshore HealthCare per ampliare l'accesso ai test di oncologia di precisione in Canada. L'accordo renderà disponibile il portafoglio di test per il cancro di Guardant attraverso la rete di cliniche di Bayshore, che serve oltre 350.000 canadesi all'anno (escluso il Québec).
La partnership include tre test chiave: Guardant360® per la selezione della terapia nel cancro avanzato, Guardant Reveal™ per la rilevazione della malattia residua minima e il monitoraggio delle recidive nel cancro in fase iniziale, e il test del sangue Shield™ per lo screening del cancro colorettale. Questa collaborazione mira a fornire ai medici tecnologie avanzate di profilazione molecolare per sviluppare piani di cura personalizzati e migliorare i risultati per i pazienti.
Guardant Health (Nasdaq: GH) se ha asociado con Bayshore HealthCare para ampliar el acceso a pruebas de oncología de precisión en Canadá. El acuerdo hará que el portafolio de pruebas de cáncer de Guardant esté disponible a través de la red de clínicas de Bayshore, que atiende a más de 350,000 canadienses anualmente (excluyendo Quebec).
La asociación incluye tres pruebas clave: Guardant360® para la selección de terapia en cáncer avanzado, Guardant Reveal™ para la detección de enfermedad residual mínima y el monitoreo de recurrencias en cáncer en etapas tempranas, y la prueba de sangre Shield™ para el cribado del cáncer colorrectal. Esta colaboración tiene como objetivo proporcionar a los médicos tecnología avanzada de perfilado molecular para desarrollar planes de atención personalizados y mejorar los resultados para los pacientes.
Guardant Health (Nasdaq: GH)는 Bayshore HealthCare와 협력하여 캐나다 전역에서 정밀 종양학 테스트에 대한 접근성을 확대하고 있습니다. 이 협약을 통해 Guardant의 암 테스트 포트폴리오가 Bayshore의 클리닉 네트워크를 통해 제공되며, 이 네트워크는 매년 350,000명 이상의 캐나다인을 지원합니다(퀘벡 제외).
이 파트너십에는 세 가지 주요 테스트가 포함됩니다: Guardant360®는 진행성 암에서 치료 선택을 위한 것이고, Guardant Reveal™는 초기 암에서 최소 잔여 질병 탐지 및 재발 모니터링을 위한 것이며, Shield™ 혈액 테스트는 대장암 선별을 위한 것입니다. 이 협력은 의사들에게 개인화된 치료 계획을 개발하고 환자 결과를 개선하기 위한 고급 분자 프로파일링 기술을 제공하는 것을 목표로 하고 있습니다.
Guardant Health (Nasdaq: GH) s'est associé à Bayshore HealthCare pour élargir l'accès aux tests d'oncologie de précision à travers le Canada. Cet accord rendra le portefeuille de tests de cancer de Guardant disponible par le biais du réseau de cliniques de Bayshore, qui dessert plus de 350 000 Canadiens chaque année (à l'exception du Québec).
Le partenariat comprend trois tests clés : Guardant360® pour la sélection de thérapie dans le cancer avancé, Guardant Reveal™ pour la détection de la maladie résiduelle minimale et le suivi des récidives dans le cancer à un stade précoce, et le test sanguin Shield™ pour le dépistage du cancer colorectal. Cette collaboration vise à fournir aux médecins une technologie avancée de profilage moléculaire pour développer des plans de soins personnalisés et améliorer les résultats pour les patients.
Guardant Health (Nasdaq: GH) hat eine Partnerschaft mit Bayshore HealthCare geschlossen, um den Zugang zu präzisen Onkologie-Tests in Kanada zu erweitern. Die Vereinbarung wird es ermöglichen, das Portfolio von Krebsuntersuchungen von Guardant über das Netzwerk von Bayshore-Kliniken anzubieten, das jährlich über 350.000 Kanadier (ohne Québec) betreut.
Die Partnerschaft umfasst drei wichtige Tests: Guardant360® zur Therapieauswahl bei fortgeschrittenem Krebs, Guardant Reveal™ zur Erkennung minimaler Restkrankheit und zur Überwachung von Rückfällen bei Krebs im Frühstadium sowie den Bluttest Shield™ zum Screening von Dickdarmkrebs. Diese Zusammenarbeit zielt darauf ab, Ärzten fortschrittliche molekulare Profilierungstechnologie zur Entwicklung personalisierter Behandlungspläne und zur Verbesserung der Patientenergebnisse zur Verfügung zu stellen.
- Expansion into Canadian market through partnership with major healthcare provider
- Access to 350,000+ potential patients annually
- Diversification of service offering with three distinct cancer testing products
- Quebec market excluded from partnership coverage
Insights
This partnership with Bayshore HealthCare represents a strategic market expansion for Guardant Health into the Canadian healthcare ecosystem. By leveraging Bayshore's established network serving over 350,000 Canadians annually (excluding Quebec), Guardant gains significant distribution capabilities without the capital expenditure required to build proprietary infrastructure.
The comprehensive scope of this agreement is particularly noteworthy. Rather than testing the market with a single product, Guardant is deploying its entire diagnostic portfolio spanning the complete cancer care continuum: Guardant360 for advanced cancer therapy selection, Guardant Reveal for minimal residual disease detection, and Shield for colorectal cancer screening. This full-spectrum approach suggests confidence in the Canadian market's receptiveness to their liquid biopsy technology.
For diagnostic companies like Guardant, test volume growth directly correlates with revenue expansion. This partnership creates a new channel for volume growth beyond their core U.S. market. While the announcement lacks financial specifics, partnerships with established healthcare providers typically accelerate market penetration compared to direct entry strategies.
The partnership structure merits attention as it may serve as a template for Guardant's approach to other international markets - prioritizing established local healthcare networks rather than building direct operations. This capital-efficient expansion model could prove valuable as the company pursues global growth opportunities.
This partnership offers substantial clinical implications for Canadian cancer patients by expanding access to Guardant's sophisticated liquid biopsy platform. Guardant's technology addresses critical needs across the oncology care spectrum:
The Guardant360 test provides comprehensive genomic profiling from a simple blood draw, identifying actionable mutations that can inform therapy selection for patients with advanced or metastatic disease. This enables precision medicine approaches without the limitations and risks of tissue biopsies.
For early-stage cancer patients, the Guardant Reveal test addresses the crucial clinical challenge of minimal residual disease (MRD) detection. By identifying microscopic disease that remains after surgery or initial treatment, clinicians can make more informed decisions about adjuvant therapy needs, potentially improving cure rates while avoiding unnecessary treatment for patients at low risk of recurrence.
Perhaps most significantly, the inclusion of the Shield blood test for colorectal cancer screening has potential population health implications. Early detection dramatically improves survival outcomes, and non-invasive screening options typically increase compliance rates compared to colonoscopy or stool-based tests.
Bayshore's community-based healthcare model is well-positioned to facilitate adoption of these tests in settings beyond traditional hospital centers, potentially reaching patient populations that might otherwise lack access to advanced molecular diagnostics.
- Guardant tests for cancer screening, recurrence monitoring and treatment selection will be available to patients through Bayshore HealthCare providers
Bayshore HealthCare provides care to over 350,000 Canadians annually (excluding
“Guardant Health is proud to partner with Bayshore HealthCare in fulfilling their mission to provide better outcomes for patients,” said Helmy Eltoukhy, Guardant chairman and co-CEO. “This partnership will give their physicians access to the latest molecular profiling technology to provide a more complete view of cancer, helping them to develop optimal personalized care plans for their patients, improve outcomes and reduce the number of lives lost to cancer.”
“Providing customized care plans for our clients is central to Bayshore Healthcare’s mission,” said Karl Frank, Divisional Director, Bayshore Specialty Rx. “This partnership will enable our healthcare providers to utilize Guardant’s precision oncology testing to help detect cancer earlier, develop a targeted treatment program for each individual, and better monitor each patient’s response to therapy, with the goal of elevating our care for patients living with cancer.”
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
About Bayshore HealthCare
Bayshore HealthCare is a Canadian-owned company and one of the country's leading home and community healthcare service providers. The company aims to enhance the quality of life, well-being, dignity and independence of Canadians of all ages. With locations across the country, including 80+ home care offices, 11 pharmacies and 100+ community care clinics, Bayshore has more than 19,000 staff members and provides care to over 350,000 clients annually. Bayshore has been a recipient of
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and any current and periodic reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250403629306/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Michael Weist
press@guardanthealth.com
+1 317-371-0035
Source: Guardant Health, Inc.
FAQ
What cancer testing services will Guardant Health (GH) provide through Bayshore HealthCare in Canada?
How many patients will have access to Guardant Health's (GH) tests through the Bayshore partnership?
What is the purpose of Guardant Health's (GH) Reveal™ blood test?
What geographical regions are covered in the Guardant Health (GH) and Bayshore HealthCare partnership?
